Oragenics
Affiliations
Acquisitions
In May 2020, Oragenics acquired Noachis Terra to “develop and commercialize TerraCoV2, a vaccine candidate which could provide specific immunity from the novel coronavirus (SARS-CoV-2).1)
COVID-19
Oragenics is developing an intranasal COVID-19 vaccine product with BioDextris.2)
In December 2021, the company extended its licensing and collaboration agreement with the National Research Council of Canada that “will enable Oragenics to pursue an intranasal vaccine designed to protect against the SARS-CoV-2 Omicron variant.”3)
1)
Abraham, J. (2020, May 4). Oragenics Acquires Noachis Terra Inc., To Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing “Spike Protein”. Oragenics. https://archive.ph/U2x2L
2)
Sullivan, M., & Golodetz, K. (2021, March 9). Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine. Business Wire; Berkshire Hathaway. https://archive.ph/QrWCj
3)
Sullivan, M. (2021, December 20). Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant. Oragenics. https://archive.ph/Q0nNC